Anapharm Europe, PharmaNet officially terminate joint venture

Download PDF Copy

Jan 27 2011

NewsGuard 100/100 Score

PharmaNet Development Group, Inc. and Anapharm Europe, S.L., both leading providers of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announced that their joint venture for the collaborative provision of bioanalytical services officially ended December 22, 2010.

In conjunction with the termination of this relationship, Dr. Maria Cruz Caturla, Anapharm Europe's majority shareholder, has purchased PharmaNet's minority ownership interest, thus becoming the sole owner of the company.

The companies will independently continue to invest in, and provide to clients, bioanalytical services in their respective laboratory facilities. Additionally, to the extent necessary, the companies will provide coordinated support for those client projects undertaken jointly during the term of the joint venture.

SOURCE PharmaNet Development Group, Inc.; Anapharm Europe, S.L.

Posted in: Business / Finance

Tags: Biotechnology, Generic Drug, Laboratory, Medical Devices, Pharmaceuticals, Pharmacology

Comments (0)

Download PDF Copy

Suggested Reading

Utilizing process Raman in optimizing cultivated meat production

Utilizing process Raman in optimizing cultivated meat production

AI-designed drug ISM5939 granted IND clearance for cancer clinical trials

AI-designed drug ISM5939 granted IND clearance for cancer clinical trials

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

UChicago scientists develop a new approach to study snoRNAs

UChicago scientists develop a new approach to study snoRNAs

Greener And Cleaner: Yeast-Green Algae Mix Improves Water Treatment

Greener And Cleaner: Yeast-Green Algae Mix Improves Water Treatment

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

CAR T cell therapy breakthroughs bring new hope for treating solid tumors

CAR T cell therapy breakthroughs bring new hope for treating solid tumors

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Engineered virus-like particles evolve for superior gene delivery efficiency